Overview

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Status:
Not yet recruiting
Trial end date:
2025-05-15
Target enrollment:
Participant gender:
Summary
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Phase:
Early Phase 1
Details
Lead Sponsor:
Anhui Provincial Hospital
Collaborator:
Leman Biotech Co., Ltd